Copyright Reports & Markets. All rights reserved.

Global Acute Ischemic Stroke Therapeutics Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Acute Ischemic Stroke Therapeutics Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Acute Ischemic Stroke Therapeutics Market Size Growth Rate by Product
      • 1.4.2 Thrombolytic Therapeutics
      • 1.4.3 Antihypertensive Therapeutics
      • 1.4.4 Antiplatelet Therapeutics
      • 1.4.5 Anticoagulants
    • 1.5 Market by End User
      • 1.5.1 Global Acute Ischemic Stroke Therapeutics Market Size Growth Rate by End User
      • 1.5.2 Hospitals
      • 1.5.3 Ambulatory Surgical Center
      • 1.5.4 Diagnostic Centers
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Acute Ischemic Stroke Therapeutics Market Size
      • 2.1.1 Global Acute Ischemic Stroke Therapeutics Revenue 2014-2025
      • 2.1.2 Global Acute Ischemic Stroke Therapeutics Sales 2014-2025
    • 2.2 Acute Ischemic Stroke Therapeutics Growth Rate by Regions
      • 2.2.1 Global Acute Ischemic Stroke Therapeutics Sales by Regions
      • 2.2.2 Global Acute Ischemic Stroke Therapeutics Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Acute Ischemic Stroke Therapeutics Sales by Manufacturers
      • 3.1.1 Acute Ischemic Stroke Therapeutics Sales by Manufacturers
      • 3.1.2 Acute Ischemic Stroke Therapeutics Sales Market Share by Manufacturers
      • 3.1.3 Global Acute Ischemic Stroke Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Acute Ischemic Stroke Therapeutics Revenue by Manufacturers
      • 3.2.1 Acute Ischemic Stroke Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Acute Ischemic Stroke Therapeutics Revenue Share by Manufacturers (2014-2019)
    • 3.3 Acute Ischemic Stroke Therapeutics Price by Manufacturers
    • 3.4 Acute Ischemic Stroke Therapeutics Manufacturing Base Distribution, Product Types
      • 3.4.1 Acute Ischemic Stroke Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Acute Ischemic Stroke Therapeutics Product Type
      • 3.4.3 Date of International Manufacturers Enter into Acute Ischemic Stroke Therapeutics Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Acute Ischemic Stroke Therapeutics Sales by Product
    • 4.2 Global Acute Ischemic Stroke Therapeutics Revenue by Product
    • 4.3 Acute Ischemic Stroke Therapeutics Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Acute Ischemic Stroke Therapeutics Breakdown Data by End User

    6 North America

    • 6.1 North America Acute Ischemic Stroke Therapeutics by Countries
      • 6.1.1 North America Acute Ischemic Stroke Therapeutics Sales by Countries
      • 6.1.2 North America Acute Ischemic Stroke Therapeutics Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Acute Ischemic Stroke Therapeutics by Product
    • 6.3 North America Acute Ischemic Stroke Therapeutics by End User

    7 Europe

    • 7.1 Europe Acute Ischemic Stroke Therapeutics by Countries
      • 7.1.1 Europe Acute Ischemic Stroke Therapeutics Sales by Countries
      • 7.1.2 Europe Acute Ischemic Stroke Therapeutics Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Acute Ischemic Stroke Therapeutics by Product
    • 7.3 Europe Acute Ischemic Stroke Therapeutics by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Acute Ischemic Stroke Therapeutics by Countries
      • 8.1.1 Asia Pacific Acute Ischemic Stroke Therapeutics Sales by Countries
      • 8.1.2 Asia Pacific Acute Ischemic Stroke Therapeutics Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Acute Ischemic Stroke Therapeutics by Product
    • 8.3 Asia Pacific Acute Ischemic Stroke Therapeutics by End User

    9 Central & South America

    • 9.1 Central & South America Acute Ischemic Stroke Therapeutics by Countries
      • 9.1.1 Central & South America Acute Ischemic Stroke Therapeutics Sales by Countries
      • 9.1.2 Central & South America Acute Ischemic Stroke Therapeutics Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Acute Ischemic Stroke Therapeutics by Product
    • 9.3 Central & South America Acute Ischemic Stroke Therapeutics by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Acute Ischemic Stroke Therapeutics by Countries
      • 10.1.1 Middle East and Africa Acute Ischemic Stroke Therapeutics Sales by Countries
      • 10.1.2 Middle East and Africa Acute Ischemic Stroke Therapeutics Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Acute Ischemic Stroke Therapeutics by Product
    • 10.3 Middle East and Africa Acute Ischemic Stroke Therapeutics by End User

    11 Company Profiles

    • 11.1 Bayer
      • 11.1.1 Bayer Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Bayer Acute Ischemic Stroke Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Bayer Acute Ischemic Stroke Therapeutics Products Offered
      • 11.1.5 Bayer Recent Development
    • 11.2 Boehringer Ingelheim
      • 11.2.1 Boehringer Ingelheim Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Boehringer Ingelheim Acute Ischemic Stroke Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Boehringer Ingelheim Acute Ischemic Stroke Therapeutics Products Offered
      • 11.2.5 Boehringer Ingelheim Recent Development
    • 11.3 Roche
      • 11.3.1 Roche Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Roche Acute Ischemic Stroke Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Roche Acute Ischemic Stroke Therapeutics Products Offered
      • 11.3.5 Roche Recent Development
    • 11.4 Sanofi
      • 11.4.1 Sanofi Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Sanofi Acute Ischemic Stroke Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Sanofi Acute Ischemic Stroke Therapeutics Products Offered
      • 11.4.5 Sanofi Recent Development
    • 11.5 Biogen
      • 11.5.1 Biogen Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Biogen Acute Ischemic Stroke Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Biogen Acute Ischemic Stroke Therapeutics Products Offered
      • 11.5.5 Biogen Recent Development
    • 11.6 Daiichi Sankyo
      • 11.6.1 Daiichi Sankyo Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Daiichi Sankyo Acute Ischemic Stroke Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Daiichi Sankyo Acute Ischemic Stroke Therapeutics Products Offered
      • 11.6.5 Daiichi Sankyo Recent Development
    • 11.7 Pfizer
      • 11.7.1 Pfizer Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Pfizer Acute Ischemic Stroke Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Pfizer Acute Ischemic Stroke Therapeutics Products Offered
      • 11.7.5 Pfizer Recent Development

    12 Future Forecast

    • 12.1 Acute Ischemic Stroke Therapeutics Market Forecast by Regions
      • 12.1.1 Global Acute Ischemic Stroke Therapeutics Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Acute Ischemic Stroke Therapeutics Revenue Forecast by Regions 2019-2025
    • 12.2 Acute Ischemic Stroke Therapeutics Market Forecast by Product
      • 12.2.1 Global Acute Ischemic Stroke Therapeutics Sales Forecast by Product 2019-2025
      • 12.2.2 Global Acute Ischemic Stroke Therapeutics Revenue Forecast by Product 2019-2025
    • 12.3 Acute Ischemic Stroke Therapeutics Market Forecast by End User
    • 12.4 North America Acute Ischemic Stroke Therapeutics Forecast
    • 12.5 Europe Acute Ischemic Stroke Therapeutics Forecast
    • 12.6 Asia Pacific Acute Ischemic Stroke Therapeutics Forecast
    • 12.7 Central & South America Acute Ischemic Stroke Therapeutics Forecast
    • 12.8 Middle East and Africa Acute Ischemic Stroke Therapeutics Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Acute Ischemic Stroke Therapeutics Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      AIS is a chronic condition characterized by the sudden loss of blood supply to a part of the brain, thus causing subsequent loss of neurological function. AIS is caused by thrombotic or embolic obstruction of the cerebral artery and is more common than hemorrhagic stroke. The global AIS therapeutics market is expected to register a low single digit market growth during the forecast period. The marginal growth rate is attributed to the lack of approved drugs in this area, the presence of alternative therapies, extensive use of generics, and unmet needs for anticoagulant reversal agents.
      Technavio's analysts forecast the global acute ischemic stroke therapeutics market to grow at a CAGR of 2.11% during the period 2017-2025.
      The global Acute Ischemic Stroke Therapeutics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of 0.021 during 2019-2025. The objectives of this study are to define, segment, and project the size of the Acute Ischemic Stroke Therapeutics market based on company, product type, end user and key regions.

      This report studies the global market size of Acute Ischemic Stroke Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Acute Ischemic Stroke Therapeutics in these regions.
      This research report categorizes the global Acute Ischemic Stroke Therapeutics market by top players/brands, region, type and end user. This report also studies the global Acute Ischemic Stroke Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Bayer
      Boehringer Ingelheim
      Roche
      Sanofi
      Biogen
      Daiichi Sankyo
      Pfizer

      Market size by Product
      Thrombolytic Therapeutics
      Antihypertensive Therapeutics
      Antiplatelet Therapeutics
      Anticoagulants
      Market size by End User
      Hospitals
      Ambulatory Surgical Center
      Diagnostic Centers

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Acute Ischemic Stroke Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Acute Ischemic Stroke Therapeutics market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Acute Ischemic Stroke Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Acute Ischemic Stroke Therapeutics submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Acute Ischemic Stroke Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Acute Ischemic Stroke Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now